Medpace Holdings, Inc. (MEDP) Stock Price & Analysis
Medpace Holdings, Inc. (MEDP) rose 1.94% to USD 466.79 as of June 10, 2026 at 02:19 UTC, according to Nexqual real-time market data.
MEDP last closed at USD 457.9; the session ranged USD 456.97–471.23 on volume of 284,277 shares. Market capitalization is $13.33B, with a 52-week range of USD 294.07–628.92 (NMS). Source: Nexqual, June 10, 2026 at 02:19 UTC.
Key Statistics (as of June 10, 2026 at 02:19 UTC)
| Price | USD 466.79 |
|---|---|
| Change | ▲ 1.94% (up) |
| Previous Close | USD 457.9 |
| Open | USD 460.36 |
| Day Range | USD 456.97 – 471.23 |
| 52-Week Range | USD 294.07 – 628.92 |
| Volume | 284,277 shares |
| Market Cap | $13.33B |
| Exchange | NMS |
Technical Analysis (MEDP)
Nexqual's technical model rates MEDP "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:19 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.35 (neutral) |
| vs SMA50 | Above (USD 454.93) |
| MACD | 4.72 (positive) |
Analyst Ratings (MEDP)
Wall Street analysts rate MEDP "Hold" based on 12 analysts, with a mean price target of USD 442.83 (range USD 329–495), per Nexqual as of June 10, 2026 at 02:19 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 442.83 |
| High Target | USD 495 |
| Low Target | USD 329 |
| Buy / Hold / Sell | 4 / 8 / 1 |
Earnings (MEDP)
| Next Earnings Date | 2026-07-20 |
|---|---|
| EPS Estimate | USD 3.96 |
| Revenue Estimate | $690.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.28 vs est 3.96 ▲ beat |
| 2025-12-31 | USD 4.67 vs est 4.23 ▲ beat |
| 2025-09-30 | USD 3.86 vs est 3.57 ▲ beat |
| 2025-06-30 | USD 3.1 vs est 3 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financials & Fundamentals (MEDP)
| Total Revenue | $2.68B |
|---|---|
| Revenue Growth (YoY) | +26.50% |
| Gross Margin | +71.90% |
| Operating Margin | +20.03% |
| Profit Margin | +17.19% |
| ROE | +77.25% |
| Debt / Equity | 24.42 |
| Current Ratio | 0.85 |
| Total Cash | $652.68M |
| Total Debt | $146.09M |
| Free Cash Flow | $490.74M |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financial Health Score (MEDP)
Nexqual rates Medpace Holdings, Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 02:19 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 20% |
| Balance Sheet | Solid — $653M cash vs $146M debt, net cash position |
| Cash Flow | Strong — FCF $491M, 19% margin |
| Efficiency | Strong — ROE 77%, ROA 17.5% |
Ownership (MEDP)
| Insider Ownership | +19.43% |
|---|---|
| Institutional Ownership | +88.93% |
| Shares Outstanding | 28.56M |
| Float | 23.00M |
| Short % of Float | +8.93% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Leadership (MEDP)
Medpace Holdings, Inc. is led by August James Troendle (age 69), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 02:19 UTC.
| CEO, President & Chairman | August James Troendle (age 69) |
|---|---|
| CFO & Treasurer | Kevin M. Brady (age 50) |
| Executive Vice President of Operations | Brad W. Hansman (age 42) |
| Associate Director of Investors Relations | Lauren Morris |
| Vice President of Business Development & Marketing | Todd Meyers |
Major Backers & Investors (MEDP)
Notable institutional backers of Medpace Holdings, Inc. include AQR Capital Management, LLC, Invesco, Wasatch Advisors LP, according to Nexqual as of June 10, 2026 at 02:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AQR Capital Management, LLC | 4.74% |
| Invesco | 3.12% |
| Wasatch Advisors LP | 2.71% |
| Renaissance Technologies | 1.77% |
| Baillie Gifford | 1.76% |
| WASATCH FUNDS TRUST-Wasatch Core Growth Fund | 0.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.46% |
| BlackRock | 11.89% |
| State Street | 2.98% |
| Geode Capital | 2.61% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
From Medpace Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
- The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
- It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KNSL | Kinsale Capital Group, Inc. | USD 303.25 | ▼ 0.94% |
| IQV | IQVIA Holdings, Inc. | USD 186.25 | ▲ 1.53% |
| ICLR | ICON plc | USD 151.82 | ▲ 1.59% |
| LNTH | Lantheus Holdings, Inc. | USD 99.98 | ▼ 0.99% |
| PODD | Insulet Corporation | USD 159.61 | ▲ 4.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:19 UTC. This page is informational and not investment advice.